Global Multiple Sclerosis Drugs Market Size study & Forecast, by Drug Class (Immunomodulators, Immunosuppressants, Interferons) by Route of Administration (Oral, Injection), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Regional Analysis, 2022-2029
Global Multiple Sclerosis Drugs Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XXX% over the forecast period 2022-2029. Multiple sclerosis is an in?ammatory immune-mediated disorder that affects nerve cells in the brain and the spinal cord, causing axonal transection, demyelination, and neurodegeneration. Some of the most often used treatments include physical therapy, muscle relaxants, antidepressants, and oral, injectable, and infused medications. Oral drugs including dimethyl fumarate, teriflunomide, and cladribine; intravenous infusion therapies like ocrelizumab; and injectable therapies like interferon-beta, glatiramer acetate, given intramuscularly or subcutaneously. The key factor driving the market growth is rising prevalence of Multiple Sclerosis disease and rising R&D investment by the market players for the drugs development that anticipated to support the market growth during forecast period.
According to the Multiple Sclerosis International Federation (MSIF), the number of patients with multiple sclerosis throughout the globe increased from 2.3 million in 2013 to 2.8 million in 2020. The demand for effective multiple sclerosis diagnosis and treatment has increased worldwide as a result of the disease's rising prevalence. Also, the rising R&D and clinical trial by the market players will create the lucrative demand for the market. For instance, For the therapy of non-relapsing secondary progressive MS (nrSPMS), relapsing forms of MS (RMS), and primary progressive MS, Sanofi is conducting a phase III clinical trial for tolebrutinib (PPMS). Sanofi anticipates submitting this medication in 2024 and 2025+, respectively, for the approved indications. Additionally, the rising government support for the treatment of multiple sclerosis is likely to increase the market growth during the forecast period. However, the high cost of Multiple Sclerosis Drugs stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Multiple Sclerosis Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the rising R&D investment, new product development, and growing demand for immunosuppressant and molecular antibody drugs. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as growing prevalence of multiple sclerosis disease and rising government initiatives in several countries to reduce the cost of treatment would create lucrative growth prospects for the Multiple Sclerosis Drugs market across Asia Pacific region.
Major market player included in this report are:
Biogen Inc.
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Merck & Co., Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
Bristol-Myers Squibb Company
Cipla Inc.
Recent Developments in the Market:
In March 2021, Janssen Pharmaceutical, Inc. revealed the U.S. FDA approval of Ponvory, an oral specific sphingosine-1-phosphate receptor 1 (S1P1) modulator to treat people with relapsing forms of MS. In comparison to Aubagio, Ponvory is more effective at lowering annual relapse rates. The company increased its range of products for the treatment of MS with the inclusion of this product in its portfolio.
Global Multiple Sclerosis Drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug Class, Route of Administration, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
Immunomodulators
Immunosuppressants
Interferons
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
According to the Multiple Sclerosis International Federation (MSIF), the number of patients with multiple sclerosis throughout the globe increased from 2.3 million in 2013 to 2.8 million in 2020. The demand for effective multiple sclerosis diagnosis and treatment has increased worldwide as a result of the disease's rising prevalence. Also, the rising R&D and clinical trial by the market players will create the lucrative demand for the market. For instance, For the therapy of non-relapsing secondary progressive MS (nrSPMS), relapsing forms of MS (RMS), and primary progressive MS, Sanofi is conducting a phase III clinical trial for tolebrutinib (PPMS). Sanofi anticipates submitting this medication in 2024 and 2025+, respectively, for the approved indications. Additionally, the rising government support for the treatment of multiple sclerosis is likely to increase the market growth during the forecast period. However, the high cost of Multiple Sclerosis Drugs stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Multiple Sclerosis Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the rising R&D investment, new product development, and growing demand for immunosuppressant and molecular antibody drugs. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as growing prevalence of multiple sclerosis disease and rising government initiatives in several countries to reduce the cost of treatment would create lucrative growth prospects for the Multiple Sclerosis Drugs market across Asia Pacific region.
Major market player included in this report are:
Biogen Inc.
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Merck & Co., Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
Bristol-Myers Squibb Company
Cipla Inc.
Recent Developments in the Market:
In March 2021, Janssen Pharmaceutical, Inc. revealed the U.S. FDA approval of Ponvory, an oral specific sphingosine-1-phosphate receptor 1 (S1P1) modulator to treat people with relapsing forms of MS. In comparison to Aubagio, Ponvory is more effective at lowering annual relapse rates. The company increased its range of products for the treatment of MS with the inclusion of this product in its portfolio.
Global Multiple Sclerosis Drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug Class, Route of Administration, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
Immunomodulators
Immunosuppressants
Interferons
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Multiple Sclerosis Drugs Market, by Region, 2019-2029 (USD Billion)
1.2.2. Multiple Sclerosis Drugs Market, by Drug Class, 2019-2029 (USD Billion)
1.2.3. Multiple Sclerosis Drugs Market, by Route of Administration, 2019-2029 (USD Billion)
1.2.4. Multiple Sclerosis Drugs Market, by Distribution Channel, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET DYNAMICS
3.1. Multiple Sclerosis Drugs Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising prevalence of multiple sclerosis disease
3.1.1.2. Growing R&D Investment
3.1.2. Market Challenges
3.1.2.1. High cost of multiple sclerosis drugs
3.1.3. Market Opportunities
3.1.3.1. Rising government support for the treatment of multiple sclerosis
CHAPTER 4. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. RISK ASSESSMENT: COVID-19 IMPACT
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
CHAPTER 6. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET, BY DRUG CLASS
6.1. Market Snapshot
6.2. Global Multiple Sclerosis Drugs Market by Drug Class, Performance - Potential Analysis
6.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
6.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
6.4.1. Immunomodulators
6.4.2. Immunosuppressants
6.4.3. Interferons
CHAPTER 7. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
7.1. Market Snapshot
7.2. Global Multiple Sclerosis Drugs Market by Route of Administration, Performance - Potential Analysis
7.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Route of Administration 2019-2029 (USD Billion)
7.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
7.4.1. Oral
7.4.2. Injection
CHAPTER 8. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
8.1. Market Snapshot
8.2. Global Multiple Sclerosis Drugs Market by Distribution Channel, Performance - Potential Analysis
8.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
8.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
8.4.1. Hospital Pharmacy
8.4.2. Retail Pharmacy
8.4.3. Online Pharmacy
CHAPTER 9. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET, REGIONAL ANALYSIS
9.1. Multiple Sclerosis Drugs Market, Regional Market Snapshot
9.2. North America Multiple Sclerosis Drugs Market
9.2.1. U.S. Multiple Sclerosis Drugs Market
9.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
9.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
9.2.2. Canada Multiple Sclerosis Drugs Market
9.3. Europe Multiple Sclerosis Drugs Market Snapshot
9.3.1. U.K. Multiple Sclerosis Drugs Market
9.3.2. Germany Multiple Sclerosis Drugs Market
9.3.3. France Multiple Sclerosis Drugs Market
9.3.4. Spain Multiple Sclerosis Drugs Market
9.3.5. Italy Multiple Sclerosis Drugs Market
9.3.6. Rest of Europe Multiple Sclerosis Drugs Market
9.4. Asia-Pacific Multiple Sclerosis Drugs Market Snapshot
9.4.1. China Multiple Sclerosis Drugs Market
9.4.2. India Multiple Sclerosis Drugs Market
9.4.3. Japan Multiple Sclerosis Drugs Market
9.4.4. Australia Multiple Sclerosis Drugs Market
9.4.5. South Korea Multiple Sclerosis Drugs Market
9.4.6. Rest of Asia Pacific Multiple Sclerosis Drugs Market
9.5. Latin America Multiple Sclerosis Drugs Market Snapshot
9.5.1. Brazil Multiple Sclerosis Drugs Market
9.5.2. Mexico Multiple Sclerosis Drugs Market
9.5.3. Rest of Latin America Multiple Sclerosis Drugs Market
9.6. Rest of The World Multiple Sclerosis Drugs Market
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Biogen Inc.
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Pfizer Inc.
10.2.3. F. Hoffmann-La Roche Ltd.
10.2.4. Novartis AG
10.2.5. Merck & Co., Inc.
10.2.6. Sanofi S.A.
10.2.7. Teva Pharmaceutical Industries Ltd.
10.2.8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
10.2.9. Bristol-Myers Squibb Company
10.2.10. Cipla Inc.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Multiple Sclerosis Drugs Market, by Region, 2019-2029 (USD Billion)
1.2.2. Multiple Sclerosis Drugs Market, by Drug Class, 2019-2029 (USD Billion)
1.2.3. Multiple Sclerosis Drugs Market, by Route of Administration, 2019-2029 (USD Billion)
1.2.4. Multiple Sclerosis Drugs Market, by Distribution Channel, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET DYNAMICS
3.1. Multiple Sclerosis Drugs Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising prevalence of multiple sclerosis disease
3.1.1.2. Growing R&D Investment
3.1.2. Market Challenges
3.1.2.1. High cost of multiple sclerosis drugs
3.1.3. Market Opportunities
3.1.3.1. Rising government support for the treatment of multiple sclerosis
CHAPTER 4. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. RISK ASSESSMENT: COVID-19 IMPACT
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
CHAPTER 6. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET, BY DRUG CLASS
6.1. Market Snapshot
6.2. Global Multiple Sclerosis Drugs Market by Drug Class, Performance - Potential Analysis
6.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
6.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
6.4.1. Immunomodulators
6.4.2. Immunosuppressants
6.4.3. Interferons
CHAPTER 7. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
7.1. Market Snapshot
7.2. Global Multiple Sclerosis Drugs Market by Route of Administration, Performance - Potential Analysis
7.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Route of Administration 2019-2029 (USD Billion)
7.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
7.4.1. Oral
7.4.2. Injection
CHAPTER 8. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
8.1. Market Snapshot
8.2. Global Multiple Sclerosis Drugs Market by Distribution Channel, Performance - Potential Analysis
8.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
8.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
8.4.1. Hospital Pharmacy
8.4.2. Retail Pharmacy
8.4.3. Online Pharmacy
CHAPTER 9. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET, REGIONAL ANALYSIS
9.1. Multiple Sclerosis Drugs Market, Regional Market Snapshot
9.2. North America Multiple Sclerosis Drugs Market
9.2.1. U.S. Multiple Sclerosis Drugs Market
9.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
9.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
9.2.2. Canada Multiple Sclerosis Drugs Market
9.3. Europe Multiple Sclerosis Drugs Market Snapshot
9.3.1. U.K. Multiple Sclerosis Drugs Market
9.3.2. Germany Multiple Sclerosis Drugs Market
9.3.3. France Multiple Sclerosis Drugs Market
9.3.4. Spain Multiple Sclerosis Drugs Market
9.3.5. Italy Multiple Sclerosis Drugs Market
9.3.6. Rest of Europe Multiple Sclerosis Drugs Market
9.4. Asia-Pacific Multiple Sclerosis Drugs Market Snapshot
9.4.1. China Multiple Sclerosis Drugs Market
9.4.2. India Multiple Sclerosis Drugs Market
9.4.3. Japan Multiple Sclerosis Drugs Market
9.4.4. Australia Multiple Sclerosis Drugs Market
9.4.5. South Korea Multiple Sclerosis Drugs Market
9.4.6. Rest of Asia Pacific Multiple Sclerosis Drugs Market
9.5. Latin America Multiple Sclerosis Drugs Market Snapshot
9.5.1. Brazil Multiple Sclerosis Drugs Market
9.5.2. Mexico Multiple Sclerosis Drugs Market
9.5.3. Rest of Latin America Multiple Sclerosis Drugs Market
9.6. Rest of The World Multiple Sclerosis Drugs Market
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Biogen Inc.
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Pfizer Inc.
10.2.3. F. Hoffmann-La Roche Ltd.
10.2.4. Novartis AG
10.2.5. Merck & Co., Inc.
10.2.6. Sanofi S.A.
10.2.7. Teva Pharmaceutical Industries Ltd.
10.2.8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
10.2.9. Bristol-Myers Squibb Company
10.2.10. Cipla Inc.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
LIST OF TABLES
TABLE 1. Global Multiple Sclerosis Drugs Market, report scope
TABLE 2. Global Multiple Sclerosis Drugs Market estimates & forecasts by Region 2019-2029 (USD Billion)
TABLE 3. Global Multiple Sclerosis Drugs Market estimates & forecasts by Drug Class 2019-2029 (USD Billion)
TABLE 4. Global Multiple Sclerosis Drugs Market estimates & forecasts by Route of Administration 2019-2029 (USD Billion)
TABLE 5. Global Multiple Sclerosis Drugs Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
TABLE 6. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 7. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 8. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 9. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 10. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 11. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 12. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 13. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 14. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 15. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 16. U.S. Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 17. U.S. Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 18. U.S. Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 19. Canada Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 20. Canada Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 21. Canada Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 22. UK Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 23. UK Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 24. UK Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 25. Germany Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 26. Germany Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 27. Germany Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 28. France Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 29. France Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 30. France Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 31. Italy Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 32. Italy Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 33. Italy Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 34. Spain Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 35. Spain Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 36. Spain Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 37. RoE Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 38. RoE Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 39. RoE Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 40. China Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 41. China Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 42. China Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 43. India Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 44. India Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 45. India Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 46. Japan Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 47. Japan Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 48. Japan Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 49. South Korea Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 50. South Korea Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 51. South Korea Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 52. Australia Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 53. Australia Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 54. Australia Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 55. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 56. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 57. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 58. Brazil Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 59. Brazil Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 60. Brazil Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 61. Mexico Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 62. Mexico Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 63. Mexico Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 64. RoLA Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 65. RoLA Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 66. RoLA Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 67. Row Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 68. Row Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 69. Row Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 70. List of secondary sources, used in the study of global Multiple Sclerosis Drugs Market
TABLE 71. List of primary sources, used in the study of global Multiple Sclerosis Drugs Market
TABLE 72. Years considered for the study
TABLE 73. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
TABLE 1. Global Multiple Sclerosis Drugs Market, report scope
TABLE 2. Global Multiple Sclerosis Drugs Market estimates & forecasts by Region 2019-2029 (USD Billion)
TABLE 3. Global Multiple Sclerosis Drugs Market estimates & forecasts by Drug Class 2019-2029 (USD Billion)
TABLE 4. Global Multiple Sclerosis Drugs Market estimates & forecasts by Route of Administration 2019-2029 (USD Billion)
TABLE 5. Global Multiple Sclerosis Drugs Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
TABLE 6. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 7. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 8. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 9. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 10. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 11. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 12. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 13. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 14. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 15. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 16. U.S. Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 17. U.S. Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 18. U.S. Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 19. Canada Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 20. Canada Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 21. Canada Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 22. UK Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 23. UK Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 24. UK Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 25. Germany Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 26. Germany Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 27. Germany Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 28. France Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 29. France Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 30. France Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 31. Italy Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 32. Italy Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 33. Italy Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 34. Spain Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 35. Spain Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 36. Spain Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 37. RoE Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 38. RoE Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 39. RoE Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 40. China Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 41. China Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 42. China Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 43. India Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 44. India Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 45. India Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 46. Japan Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 47. Japan Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 48. Japan Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 49. South Korea Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 50. South Korea Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 51. South Korea Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 52. Australia Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 53. Australia Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 54. Australia Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 55. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 56. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 57. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 58. Brazil Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 59. Brazil Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 60. Brazil Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 61. Mexico Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 62. Mexico Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 63. Mexico Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 64. RoLA Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 65. RoLA Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 66. RoLA Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 67. Row Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 68. Row Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 69. Row Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 70. List of secondary sources, used in the study of global Multiple Sclerosis Drugs Market
TABLE 71. List of primary sources, used in the study of global Multiple Sclerosis Drugs Market
TABLE 72. Years considered for the study
TABLE 73. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
LIST OF FIGURES
FIG 1. Global Multiple Sclerosis Drugs Market, research methodology
FIG 2. Global Multiple Sclerosis Drugs Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Multiple Sclerosis Drugs Market, key trends 2021
FIG 5. Global Multiple Sclerosis Drugs Market, growth prospects 2022-2029
FIG 6. Global Multiple Sclerosis Drugs Market, porters 5 force model
FIG 7. Global Multiple Sclerosis Drugs Market, pest analysis
FIG 8. Global Multiple Sclerosis Drugs Market, value chain analysis
FIG 9. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
FIG 10. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
FIG 11. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
FIG 12. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
FIG 13. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
FIG 14. Global Multiple Sclerosis Drugs Market, regional snapshot 2019 & 2029
FIG 15. North America Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
FIG 16. Europe Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
FIG 17. Asia pacific Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
FIG 18. Latin America Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
FIG 19. Global Multiple Sclerosis Drugs Market, company Market share analysis (2021)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
FIG 1. Global Multiple Sclerosis Drugs Market, research methodology
FIG 2. Global Multiple Sclerosis Drugs Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Multiple Sclerosis Drugs Market, key trends 2021
FIG 5. Global Multiple Sclerosis Drugs Market, growth prospects 2022-2029
FIG 6. Global Multiple Sclerosis Drugs Market, porters 5 force model
FIG 7. Global Multiple Sclerosis Drugs Market, pest analysis
FIG 8. Global Multiple Sclerosis Drugs Market, value chain analysis
FIG 9. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
FIG 10. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
FIG 11. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
FIG 12. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
FIG 13. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
FIG 14. Global Multiple Sclerosis Drugs Market, regional snapshot 2019 & 2029
FIG 15. North America Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
FIG 16. Europe Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
FIG 17. Asia pacific Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
FIG 18. Latin America Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
FIG 19. Global Multiple Sclerosis Drugs Market, company Market share analysis (2021)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
